GILD vs IPCXR · P/E 18, rev $7.80B vs rev $100.0M
Gilead Sciences Inc (GILD) versus Inflection Point Acquisition Corp. III Rights (IPCXR) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Inflection Point Acquisition Corp. III Rights (IPCXR) common stock listed on US.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported IPCXR revenue for 2025-09-30 was $100.0M. Net income was -$90.8K. IPCXR currently screens at market cap $0.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. IPCXR currently screens at market cap $0.
Not investment advice. Open the GILD and IPCXR stock pages for the full models.
Not investment advice.